Role of thrombopoietin stimulating agents(Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE

Role of thrombopoietin stimulating agents(Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE

Introduction: Immune thrombocytopenia is a frequent hematologic manifestation in systemic lupus erythematosus (SLE). Corticosteroids are the first line of treatment for moderate to severe thrombocytopenia in this disease, in conjunction with antimalarials or other immunosuppressants. In particular c...

Full description

Bibliographic Details
Main Authors:	Toro Vélez, Esteban, Nova Escobar, Santiago, Jaramillo Arroyave, Daniel
Format:	Article
Language:	Spanish
Published:	Universidad de Antioquia 2021-07-01
Series:	Iatreia
Subjects:	lupus erythematosus systemic purpura thrombo-cytopenic idiopathic receptors thrombopoietin
Online Access:	https://revistas.udea.edu.co/index.php/iatreia/article/view/343464/20804848

Similar Items

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2018-01-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Eltrombopag Use in Children with Persistent and Chronic Primary Immune Thrombocytopenia in a Portuguese Pediatric Center
by: Caroline Lopes, et al.
Published: (2024-04-01)

Advances in management of pediatric chronic immune thrombocytopenia: a narrative review
by: Jae Min Lee
Published: (2023-07-01)

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
by: A. G. Solodovnikov, et al.
Published: (2020-12-01)

Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency
by: Laura Scaramucci, et al.
Published: (2016-02-01)

Serum thrombopoietin and cMpl expression in thrombocytopenia of different etiologies
by: Fabrizio Vianello, et al.
Published: (2014-03-01)

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?
by: Jefri Pratama Susanto
Published: (2016-11-01)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
by: Fernanda Lubiana de Oliveira, et al.
Published: (2023-01-01)

Clinical Presentation and Therapy of Primary Immune Thrombocytopenia Resistant to Splenectomy
by: Aleksandar Kara-Jovanović, et al.
Published: (2020-04-01)

Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report
by: Kouki Hoshino, et al.
Published: (2019-04-01)

The role of hydroxychloroquine as a steroid-sparing agent in the treatment of immune thrombocytopenia: A review of the literature
by: Fatemeh Mohammadpour, et al.
Published: (2018-01-01)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
by: Cy R. Wilkins, et al.
Published: (2022-03-01)

Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
by: Angelica Maria Garzon, et al.
Published: (2015-08-01)

Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice
by: Monica Carpenedo, et al.
Published: (2015-02-01)

Aplastic anemia with thrombopoietin gene mutation successfully treated with romiplostim monotherapy
by: Niranjan Gurunath Hegde, et al.
Published: (2023-01-01)

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
by: Qiuhua Zhu, et al.
Published: (2021-08-01)

Idiopathic Thrombocytopenic Purpura as Initial Manifestation of Systemic Lupus Erythematosus: A Case Report
by: Fatih Bağcıer, et al.
Published: (2016-08-01)

Idiopathic thrombocytopenic purpura: laboratory diagnosis and management
by: Alvina
Published: (2011-08-01)

Idiopathic thrombocytopenic purpura: laboratory diagnosis and management
by: Alvina Alvina
Published: (2016-02-01)

Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
by: Sven R. Olson, et al.
Published: (2019-08-01)

Hepatitis C virus-associated thrombocytopenia is not related to serum thrombopoietin levels
by: Afifi Ola, et al.
Published: (2007-01-01)

An Analysis of the Serum Metabolomic Profile for the Radiomitigative Effect of the Thrombopoietin Receptor Agonist Romiplostim in Lethally Whole-Body-Irradiated Mice
by: Yoshiaki Sato, et al.
Published: (2022-02-01)

An Idiopathic Thrombocytopenic Purpura Patient Treated With Homeopathy: A Case Report
by: Belinda Gousta, et al.
Published: (2016-05-01)

Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
by: Olga S. Levchenkova, et al.
Published: (2023-03-01)

The thrombopoietin receptor: revisiting the master regulator of platelet production
by: Ian S. Hitchcock, et al.
Published: (2021-08-01)

Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia
by: Hyun Ji Lim, et al.
Published: (2021-04-01)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-12-01)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-11-01)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
by: Romain Gellens, et al.
Published: (2018-01-01)

CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
by: E. A. Pyadushkina, et al.
Published: (2016-02-01)

Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
by: Alexandra Schifferli, et al.
Published: (2019-06-01)

The Use of High Dose Eltrombopag in the Management of Sepsis-Associated Thrombocytopenia in Critically Ill Patients
by: Hasan Md. Jahidul, et al.
Published: (2019-11-01)

Recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: A clinical study
by: Yu Liu, et al.
Published: (2020-09-01)

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
by: Monica Carpenedo, et al.
Published: (2023-02-01)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis
by: Joyce Tumaini Massaro, et al.
Published: (2019-10-01)

A cross-sectional study on thrombopoietin levels in immune thrombocytopenia and its correlation with platelet count, megakaryocytes, and treatment response
by: Gurleen Oberoi, et al.
Published: (2022-01-01)

Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
by: Jiwon Shin, et al.
Published: (2023-05-01)

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
by: Adam Cuker, et al.
Published: (2021-01-01)

Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin
by: Yahan Li, et al.
Published: (2024-04-01)